Subjects -> MEDICAL SCIENCES (Total: 8196 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - DENTISTRY (266 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (177 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2241 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)

RHEUMATOLOGY (76 journals)

Showing 1 - 76 of 76 Journals sorted alphabetically
ACR Open Rheumatology     Open Access   (Followers: 5)
Advances in Rheumatology     Open Access   (Followers: 3)
African Journal of Rheumatology     Full-text available via subscription  
Aktuelle Rheumatologie     Hybrid Journal   (Followers: 2)
Annals of Rheumatology and Autoimmunity     Open Access   (Followers: 3)
Annals of the Rheumatic Diseases     Hybrid Journal   (Followers: 34)
Archives of Osteoporosis     Hybrid Journal   (Followers: 1)
Arthritis & Rheumatology     Hybrid Journal   (Followers: 64)
Arthritis Care & Research     Hybrid Journal   (Followers: 37)
Arthritis Research & Therapy     Open Access   (Followers: 14)
Australasian Musculoskeletal Medicine     Full-text available via subscription   (Followers: 5)
Best Practice & Research Clinical Rheumatology     Hybrid Journal   (Followers: 17)
BMC Musculoskeletal Disorders     Open Access   (Followers: 29)
BMC Rheumatology     Open Access   (Followers: 4)
Case Reports in Rheumatology     Open Access   (Followers: 10)
Clinical and Experimental Rheumatology     Full-text available via subscription   (Followers: 3)
Clinical Medicine Insights : Arthritis and Musculoskeletal Disorders     Open Access   (Followers: 3)
Clinical Rheumatology     Hybrid Journal   (Followers: 21)
Current Opinion in Rheumatology     Hybrid Journal   (Followers: 13)
Current Reviews in Musculoskeletal Medicine     Open Access   (Followers: 13)
Current Rheumatology Reports     Hybrid Journal   (Followers: 3)
Current Rheumatology Reviews     Hybrid Journal   (Followers: 4)
Current Treatment Options in Rheumatology     Hybrid Journal  
Egyptian Rheumatologist     Open Access   (Followers: 1)
Egyptian Rheumatology and Rehabilitation     Open Access   (Followers: 2)
Forum Reumatologiczne     Hybrid Journal  
Future Rheumatology     Full-text available via subscription   (Followers: 1)
Gait & Posture     Hybrid Journal   (Followers: 17)
Indian Journal of Rheumatology     Open Access   (Followers: 1)
Indonesian Journal of Rheumatology     Open Access  
International Journal of Clinical Rheumatology     Open Access   (Followers: 4)
International Journal of Rheumatic Diseases     Hybrid Journal   (Followers: 2)
International Journal of Rheumatology     Open Access   (Followers: 6)
International Musculoskeletal Medicine     Hybrid Journal   (Followers: 7)
Internet Journal of Rheumatology and Clinical Immunology     Open Access   (Followers: 4)
JCR Journal of Clinical Rheumatology     Hybrid Journal   (Followers: 7)
Journal of Musculoskeletal Research     Hybrid Journal   (Followers: 9)
Journal of Orthopedics & Rheumatology     Open Access  
Journal of Rheumatology     Open Access   (Followers: 32)
Modern Rheumatology     Hybrid Journal   (Followers: 4)
Modern Rheumatology Case Reports     Hybrid Journal  
Multiple Sclerosis and Related Disorders     Hybrid Journal   (Followers: 8)
Musculoskeletal Care     Hybrid Journal   (Followers: 19)
MYOPAIN. A journal of myofascial pain and fibromyalgia     Hybrid Journal   (Followers: 16)
Nature Reviews Rheumatology     Full-text available via subscription   (Followers: 25)
OA Arthritis     Open Access   (Followers: 1)
OA Inflammation     Open Access  
Open Access Rheumatology: Research and Reviews     Open Access   (Followers: 3)
Open Journal of Orthopedics and Rheumatology     Open Access  
Open Journal of Rheumatology and Autoimmune Diseases     Open Access   (Followers: 4)
Open Rheumatology Journal     Open Access  
Orthopädie & Rheuma     Full-text available via subscription  
Osteoarthritis and Cartilage     Full-text available via subscription   (Followers: 20)
Osteoarthritis and Cartilage Open     Open Access  
Osteologie     Hybrid Journal  
Osteoporosis and Sarcopenia     Open Access  
Pain. Joints. Spine     Open Access   (Followers: 1)
Reumatismo     Open Access  
Reumatología Clínica (English Edition)     Full-text available via subscription  
Revista Argentina de Reumatología     Open Access  
Revista Colombiana de Reumatologia     Open Access  
Revista Colombiana de Reumatología (English Edition)     Hybrid Journal  
rheuma plus     Hybrid Journal  
Rheumatic Disease Clinics of North America     Full-text available via subscription   (Followers: 4)
Rheumatica Acta: Open Access     Open Access  
Rheumatology     Hybrid Journal   (Followers: 33)
Rheumatology & Autoimmunity     Open Access   (Followers: 3)
Rheumatology Advances in Practice     Open Access   (Followers: 1)
Rheumatology and Therapy     Open Access   (Followers: 3)
Rheumatology International     Hybrid Journal   (Followers: 3)
Rheumatology Practice and Research     Open Access  
RMD Open     Open Access   (Followers: 1)
Scandinavian Journal of Rheumatology     Hybrid Journal   (Followers: 5)
Seminars in Arthritis and Rheumatism     Hybrid Journal   (Followers: 8)
The Lancet Rheumatology     Hybrid Journal  
Zeitschrift fur Rheumatologie     Hybrid Journal   (Followers: 6)
Similar Journals
Journal Cover
Clinical Medicine Insights : Arthritis and Musculoskeletal Disorders
Journal Prestige (SJR): 0.537
Citation Impact (citeScore): 2
Number of Followers: 3  

  This is an Open Access Journal Open Access journal
ISSN (Print) 1179-5441
Published by Sage Publications Homepage  [1174 journals]
  • The Impact of Metabolic Syndrome on Quality of Life Among Individuals With
           Knee Osteoarthritis Living in Egypt

    • Authors: Sara F. Samaan, Sara I. Taha
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Background:Several studies have linked metabolic syndrome (MetS) to osteoarthritis (OA), but they have not looked into how MetS can affect the health-related quality of life (HRQOL) of OA individuals.Objectives:We aimed to assess the association of MetS and its components, including obesity, hypertension, hyperglycemia, and dyslipidemia, with HRQOL among Egyptians with knee OA.Methods:This cross-sectional study comprised 116 adult Egyptian participants with knee OA. They were divided into 2 groups based on whether or not they had the MetS. All participants were subjected to a thorough medical history taking and a detailed medical examination. The Kellgren and Lawrence (K/L) scale evaluated OA in all individuals using anteroposterior knee radiographs. The Health Assessment Questionnaire-Disability Index (HAQ-DI) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were used to assess participants’ HRQOL; their higher scores indicate more disability. Spearman rank and Pearson’s correlation analyses were used to assess the association between variables.Results:Diabetes, hypertension, dyslipidemia, and obesity were significantly associated with the OA + MetS group with a prevalence of 77.6%, 82.8%, 77.6%, and 50.0%, respectively. According to the K/L scale, 70.7% of the OA + MetS group had grade IV knee affection. The HAQ-DI and WOMAC scores were significantly (P 
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-05-25T05:51:27Z
      DOI: 10.1177/11795441221097361
      Issue No: Vol. 15 (2022)
  • Representation Rate and Management of Gout for Patients Discharged From
           Emergency Departments in Illawarra Shoalhaven Local Health District

    • Authors: Aravinthan Loganathan, Arupam Raman, Natalia Berlinski, John Riordan
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Introduction:The estimated prevalence of gout in Western societies is 2.7% to 6.7%. In Australia, there have been increasing rates of hospitalisations for gout flares. Urate-lowering therapy (ULT) is effective in reducing urate burden, which can prevent gout flares and destructive arthropathy. This study assessed the representation rate of patients presenting to the Emergency Department (ED) with crystal arthropathy and the utilisation of ULT in the community for patients with a pre-existing history of gout.Methods:A retrospective review of electronic records of patients presenting to the ED from the Illawarra Shoalhaven Local Health District was performed. Patients included were coded as per the 10th revision of the International Classification of Diseases coding for crystal arthropathyResults:In all, 18.8% of all crystal arthropathy encounters to the ED were repeat presentations. Of the 70% of patients with a history of gout, only 30.8% were on ULT.Discussion:Despite evidence-based recommendations for a ‘treat-to-target’ approach, most patients with a previous history of gout were not on ULT. One in five encounters were re-presentations for crystal arthropathy. Effective adherence to treatment guidelines may reduce the number of repeat encounters for gout flare in the ED.
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-05-24T05:02:09Z
      DOI: 10.1177/11795441221097351
      Issue No: Vol. 15 (2022)
  • A Retrospective Observational Cohort Study of Periprosthetic Hip Infection
           Treated by one-stage Method Including Cases With Bone Graft Reconstruction

    • Authors: Ricardo Issler Unfried, Luciana Maria Fontanari Krause, Helen Minussi Cezimbra, Liliane Souto Pacheco, João Alberto Larangeira, Tiango Aguiar Ribeiro
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Purpose:Prosthetic joint infection (PJI) is a devastating complication that can affect hip arthroplasty. Its treatment is extremely difficult, and issues regarding the optimal treatment remain unanswered. This study intended to show the effectiveness of the one-stage treatment of PJI.Materials and Methods:A retrospective observational cohort study performed from July 2014- August 2018. All patients with suspected PJI were included. Major and minor criteria developed by the International Consensus on Periprosthetic Joint Infection (ICPJI) was used to define infection. Laboratory tests and image exams were performed, and all patients were followed for at least 2 years.Outcomes:Success rate (2018 ICPJI definition to success) in treatment of PJI using one-stage revision method. Clinical and functional outcomes defined by Harris Hip Score (HHS).Results:Thirty-one patients were screened and 18 analyzed. 69.85 ± 9.76 years was the mean age. Mean follow-up time was 63.84 ± 18.55 months. Ten patients had acetabular defects and required bone graft reconstruction. Sixteen patients were classified as Tier 1, 1 as Tier 3D, and as 1 Tier 3E. Almost 90% of patients submitted to one-stage revision with acetabulum graft reconstruction were free of infection. The overall infection survival rate was 78.31±6.34 months. Candida albicans and sinus tract were statistically significant in univariate Cox’s analysis. The predictor of one-stage revision surgery failure that remained final Cox’s regression model was C. albicans (hazard ratio [HR]: 4.47).Conclusion:Treatment through one-stage revision surgery associated with 6 months of antimicrobial is a viable option with acceptable results even when bone graft reconstruction is necessary. C. albicans was a strong predictor of failure in this cohort.
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-05-05T05:51:01Z
      DOI: 10.1177/11795441221090344
      Issue No: Vol. 15 (2022)
  • Can Complete Blood Count Picture Tell Us More About the Activity of
           Rheumatological Diseases'

    • Authors: Sara I Taha, Sara F Samaan, Rehab Ali Ibrahim, Nouran M Moustafa, Eman M El-Sehsah, Mariam K Youssef
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Background:In clinical practice, distinguishing disease activity in patients with rheumatological illnesses is challenging.Objectives:We aimed to investigate clinical associations of hemogram-derived indices, namely: red cell distribution width (RDW), mean platelet volume (MPV), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII) with disease activity in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS).Methods:In 250 patients with rheumatological disease and 100 healthy age-matched controls, we investigated disease activity scores and indicators and evaluated their association with hemogram-derived indices values.Results:Compared with the control group, RDW, MPV, and PLR significantly increased (P  .05). RDW and MPV showed significant changes (P 
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-04-23T05:40:47Z
      DOI: 10.1177/11795441221089182
      Issue No: Vol. 15 (2022)
  • Ingredients of a Natural Oral Nutritional Supplement and Their Role in the
           Treatment of Osteoarthritis

    • Authors: Krish Tejas Bharat, Navdeep Singh Manhas, James Gutcho, Joshua Lin, Sumon Bhattacharyya, Robertus Kounang
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Osteoarthritis is a prevalent degenerative disease affecting a large portion of the world’s aging population. Currently, nonsteroidal anti-inflammatory drugs and acetaminophen are first-line medications for treating osteoarthritis patients’ pain. However, several studies have noted that while these medications control pain they do not halt progressive degeneration and tend to have an unfavorable side-effect profile with prolonged use. Recently, due to their more favorable side-effect profiles, herbal alternatives for controlling osteoarthritis symptoms and for alleviating the progression of the disease are being increasingly studied. Synogesic is a newly developed herbal supplement blend by renowned orthopedic surgeons and physiatrists consisting of turmeric, rutin, ginger root, vitamin C, vitamin D, and boswellia extracts. A study by Sharkey et al. has commented on the efficacy of the blend on the patients with knee osteoarthritis. So far, a review on the ingredients of the blend has not yet carried outbeen. By exploring prominent literature databases including PubMed and ScienceDirect, our aim is to write a narrative review to explore the individual ingredients of this blend and delve into their characteristics, as well as the most recent literature on their mechanism and efficacy in patients with osteoarthritis. Through this, we hope to inform clinicians and patients alike on relevant up-to-date research on the supplement and provide insight on the potential for this supplement for alleviating the disease course of patients with osteoarthritis.
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-03-25T09:48:10Z
      DOI: 10.1177/11795441211063365
      Issue No: Vol. 15 (2022)
  • Effect of Prophylactic Dose of Trimethoprim-Sulfamethoxazole on Serum
           Creatinine in Japanese Patients With Connective Tissue Diseases

    • Authors: Rui Kawato, Ryo Rokutanda, Masato Okada, Masakazu Matsushita, Ken Yamaji, Naoto Tamura
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Objectives:At normal doses of trimethoprim-sulfamethoxazole (TMP/SMX), trimethoprim inhibits tubular creatinine secretion, leading to a rapid but reversible increase in serum creatinine (SCr). Although patients with connective tissue diseases are often in the state of immunosuppression and TMP/SMX is an important prophylactic drug, clinicians often have to stop or reduce the dosage due to concerns regarding its effect on renal function. This study aimed to evaluate the effect of a prophylactic dose of TMP/SMX on SCr in Japanese patients with connective tissue diseases, the extent of SCr level elevation and the independent risk factors for creatinine elevation.Methods:A retrospective cohort study was undertaken. Participants included patients with connective tissue diseases who were treated with a prophylactic dose of TMP/SMX between 2004 and 2018. Using single and multiple regression analyses, the risk factors that affected SCr elevation were evaluated.Results:A total of 262 patients, females, n = 181; age, median (range) = 59 (19-89) years, were included. The median baseline SCr level before treatment was 0.62 (0.16-2.1) mg/dL. The median SCr elevation value was 0.07 (−0.54 to 0.84) mg/dL in 4 weeks after TMP/SMX initiation. Five (2%) participants had ⩾0.3 mg/dL SCr elevation. Multiple regression analyses, including age, baseline SCr, diuretic use, nonsteroidal anti-inflammatory drug use and diabetes mellitus, indicated that baseline SCr and advanced age were independent risk factors of SCr elevation.Conclusions:These results demonstrated that baseline SCr and advanced age were associated with SCr elevation by a prophylactic dose of TMP/SMX. However, a prophylactic dose of TMP/SMX rarely elevated the SCr level significantly. Therefore, other causes can be considered if patients show an SCr elevation ⩾0.3 mg/dL.
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-03-23T09:23:01Z
      DOI: 10.1177/11795441221085141
      Issue No: Vol. 15 (2022)
  • Associations Between Physical Activity, Self-reported Joint Function, and
           Molecular Biomarkers in Working Age Individuals With Hip and/or Knee

    • Authors: Elin Östlind, Frida Eek, Kjerstin Stigmar, Anita Sant’Anna, Eva Ekvall Hansson, André Struglics
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Objective:Previous research has suggested an association between physical activity (PA), joint function, and molecular biomarkers, but more studies are needed. The aim of this study was to explore the associations between PA or self-reported joint function and molecular biomarkers of cartilage and inflammation in individuals with hip and/or knee osteoarthritis (OA). Specific objectives were to explore the correlations between (1) the change over 3 months in self-reported PA/joint function and the change in molecular biomarkers (2) objectively measured PA and molecular biomarkers measured at 3-month follow-up.Design:Working age participants (n = 91) were recruited from a cluster randomized controlled trial. Self-reported PA, joint function, and serum samples were collected at baseline and after 3 months. Serum concentrations of the inflammatory marker C-reactive protein (CRP) and the cartilage markers Alanine-Arginine-Glycine-Serine (ARGS)-aggrecan, cartilage oligomeric matrix protein (COMP), and type II collagen C2C were analyzed by immunoassays. Objectively measured PA (steps/day) was collected during 12 weeks from activity trackers used by 53 participants. Associations were analyzed with Spearman’s rank correlation.Results:There was a weak negative correlation between the change in self-reported PA and the change in COMP (rs = −0.256, P = .040) but not for the other molecular biomarkers. There were no correlations between the change in self-reported joint function and the change in molecular biomarkers or between the average steps/day and the molecular biomarkers at follow-up (rs ⩽ −0.206, P ⩾ .06).Conclusion:In general, no or only weak associations were found between PA/joint function and molecular biomarkers. Future research recommends including participants with lower PA, extend the follow-up, and use a design that allows comparisons.
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-03-23T09:20:34Z
      DOI: 10.1177/11795441221081063
      Issue No: Vol. 15 (2022)
  • Colchicine May Interfere With the Efficacy of the Adenoviral
           Vector–Based Vaccine for COVID-19

    • Authors: Cheng-Wei Lin
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Under the ongoing COVID-19 pandemic, vaccines have become the crucial players to reduce the spread of the infection. Among them, the ChAdOx1 nCoV-19 vaccine is an adenoviral vector vaccine with an overall efficacy of 70.4% in protection. The engineered adenovirus contains the SARS-CoV-2 spike protein gene and pushes its DNA into the vaccinated cell’s nucleus and subsequently, the spike protein can be made. During vaccination, the genome transition of adenovirus is influenced by the architecture and dynamics of the microtubule. Colchicine can alter microtubule dynamics by suppressing microtubule dynamics at lower concentrations and inducing depolymerization of microtubules at higher concentrations. Accordingly, the delivery of the genome to the vaccinated cell’s nucleus by the adenoviral vector could be hindered under the presence of colchicine. Nevertheless, colchicine is a common medication for gout therapy worldwide, and though not recommended by guidelines, colchicine has even been taken into consideration as a possible therapeutic option for COVID-19 infection. Given the above reasons and the worldwide use of colchicine, the impact of colchicine on the efficacy of the COVID-19 vaccine via adenoviral vector should be viewed cautiously.
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-03-23T09:18:56Z
      DOI: 10.1177/11795441221081061
      Issue No: Vol. 15 (2022)
  • Prevalence of Osteoporosis Among Iranian Postmenopausal Women: A
           Systematic Review and Meta-analysis

    • Authors: Tayebeh Eghbali, Kamel Abdi, Mahboubeh Nazari, Esmaeil Mohammadnejad, Reza Ghanei Gheshlagh
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Objectives:Osteoporosis is the most common metabolic bone disease. It is considered the silent epidemic, with high prevalence after menopause, in the current time. Different studies conducted in Iran have reported different prevalence. The present systematic review and meta-analysis aims to estimate the overall prevalence of osteoporosis in Iranian postmenopausal women.Methods:The national scientific databases Scientific Information Database and MagIran and the international scientific databases PubMed, Web of Science, and Scopus were searched for related articles without any time limitation. The keywords osteopenia, osteoporosis, post menopause, OP, bone mineral density, and Iran along with their combinations were used in the search. The inconsistency in the data was examined using I2 test. The data were analyzed using the meta-analysis method and the random-effects model in Stata software, version 14.Results:The analysis of 26 articles with a sample size of 6735 showed that the prevalence of osteoporosis and osteopenia in Iranian postmenopausal women is, respectively, 33.70% (95% CI [confidence interval]: 22.68-44.73) and 47.60% (95% CI: 32.88-62.32). The pooled prevalence of osteoporosis in the spine and in the femur bone was 31.99% and 15.93%, respectively. Also, the prevalence of osteopenia in the spine and in the femur bone was 22.48% and 39.88%, respectively.Conclusion:Osteoporosis and osteopenia are highly prevalent in Iranian postmenopausal women to the extent that one-third of women suffer from osteoporosis and nearly half of them suffer from osteopenia. It seems essential to teach a healthy lifestyle to these women to reduce the prevalence of these issues.
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-03-10T11:14:02Z
      DOI: 10.1177/11795441211072471
      Issue No: Vol. 15 (2022)
  • Open-Label Pilot Study of a Single Intra-Articular Injection of
           Mannitol-Modified Cross-Linked Hyaluronic Acid (HANOX-M-XL) for the
           Treatment of the First Metatarsophalangeal Osteoarthritis (Hallux
           Rigidus): The REPAR Trial

    • Authors: Laurent Galois, Jean-Yves Coillard, Jérôme Porterie, Sylvie Melac-Ducamp, Thierry Conrozier
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Purpose:The purpose of this study was to obtain information on safety and short-term efficiency of a single intra-articular injection of mannitol-modified cross-linked hyaluronic acid (HANOX-M-XL) in patients with painful first metatarsophalangeal joint osteoarthritis (1stMTPJ-OA).Methods:The study involved an observational, single-arm, prospective multicentre trial, with a 3-month follow-up. Inclusion criteria were patients with symptomatic 1st MTPJ-OA not relieved by analgesics and / or non-steroidal-anti-inflammatory drugs and / or foot orthotic. All patients received a single, imaging-guided intra-articular (IA) injection of 1 mL of HANOX-M-XL in the 1st MTPJ. The primary outcome was the change in pain between the date of injection and month 3. The secondary outcomes were the patient assessment of effectiveness, the decrease in painkiller use and the influence of the radiographic score on the clinical efficacy.Results:Sixty-five participants (72.3% women, mean age = 60) were included in the trial. Coughlin-Shurnas radiological grade was 1 in 28 patients, 2 in 29, and 3 in 6. At baseline and month 3, the average pain (0-10) was 6.5 ± 1.8 and 2.8 ± 2.3, respectively. The change in pain score was highly significant (−3.1 ± 2.9; P 
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-03-10T11:07:54Z
      DOI: 10.1177/11795441211055882
      Issue No: Vol. 15 (2022)
  • Problems to Consider Before Determining the Regimen of the Treatment for
           Juvenile Systemic Sclerosis Treatment: A Case Report Where Tocilizumab
           Monotherapy Succeeded Efficiently and Safely

    • Authors: Masanori Funauchi, Koji Kinoshita
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Juvenile systemic sclerosis (SSc) is a rare condition that results in various disorders, including growth retardation and learning disabilities in addition to impaired quality of life due to fibrosis and microvascular disorders in multiple organs. Recently, efficacies of immunosuppressants such as cyclophosphamide and mycophenolate mofetil, as well as biological agents, have been reported in adult patients with SSc. However, there has been no consensus in the treatment of juvenile SSc due to its rarity and the fact that skin sclerosis may be self-limiting in some patients. Here, we present a case of 13-year-onset SSc with growth retardation and learning disabilities, in addition to skin sclerosis, interstitial lung disease, and possible myocardial fibrosis that was successfully treated with tocilizumab monotherapy without remarkable adverse reactions. As careful case-by-case management of patient’s growth and education along with standard treatment is needed, the documentation of such case is important for the evaluation of the efficient and safe therapy for juvenile SSc.
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-03-01T09:46:13Z
      DOI: 10.1177/11795441211066307
      Issue No: Vol. 15 (2022)
  • Musculoskeletal Manifestations of Sarcoidosis

    • Authors: Georges El Hasbani, Imad Uthman, Ali SM Jawad
      Abstract: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Volume 15, Issue , January-December 2022.
      Since its initial description in the late 19th century, sarcoidosis has been extensively studied. Although the general mechanism of immune activation is known, many details especially in the context of disease associations are still missing. One of such associations is the musculoskeletal complications that are widely variable in terms of presentation and response to treatment. Sarcoidosis can involve the joints leading to acute and, less commonly chronic, arthritis. While acute arthritis is mostly self-resolving in nature, chronic arthritis may lead to deformity and destruction of the joint. Sarcoidosis can also involve the muscles, leading to different pathologies primarily categorized according to the clinical presentation, despite the efforts to find a new classification based on imaging, histological, and clinical findings. The bones can be directly and indirectly affected. Different types of bone lesions have been described, although around half of these patients remain asymptomatic. Osteoporosis, increased risk of fractures, hypercalcemia, and hypercalciuria are examples of the indirect effect of sarcoidosis on the bones, possibly contributed to elevated levels of calcitriol. Nevertheless, sarcoidosis can be associated with small-vessel, medium-vessel, and large vessel vasculitis, although it is frequently difficult to differentiate between the co-existence of a pure vasculitis and sarcoidosis and sarcoid vasculitis.
      Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
      PubDate: 2022-02-15T06:44:06Z
      DOI: 10.1177/11795441211072475
      Issue No: Vol. 15 (2022)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-